The Meals and Drug Management has refused to study an utility from the biotech corporate Moderna to approve its mRNA-based flu vaccine.
The company’s choice, which Moderna introduced in a press unencumber on Feb. 10, 2026, is the most recent step in efforts by means of federal well being officers beneath Well being and Human Services and products Secretary Robert F. Kennedy Jr. to disrupt longstanding public well being practices on the subject of vaccine get entry to and approval, in addition to to reshape the general public’s belief of vaccine protection.
Vaccines in accordance with mRNA got here to the vanguard within the early days of the COVID-19 pandemic, however researchers at the moment are the use of the generation to create different vaccines, in addition to remedies for illnesses reminiscent of most cancers and autoimmune issues. The Nobel Prize-winning generation could also be particularly promising for flu as a result of vaccines can also be evolved abruptly every season to compare mutating influenza traces.
Then again, Kennedy and different federal well being officers, together with on the FDA, have expressed explicit skepticism towards mRNA-based vaccines, elevating protection considerations whilst offering no credible knowledge on their well being dangers, and defunding analysis on their construction.
The Dialog requested Ana Santos Rutschman, a Villanova College regulation professor and vaccine coverage knowledgeable, to provide an explanation for the importance of the FDA’s choice and the way it suits into the abruptly converting panorama of public well being coverage.
What precisely did the FDA do, and why is it ordinary?
In December 2025, Moderna submitted an utility to the FDA to approve an mRNA flu vaccine for adults age 50 and older. The vaccine have been examined in medical trials together with greater than 40,000 folks. Based on the appliance, the company despatched Moderna a “refusal-to-file” letter, dated Feb. 3, 2026. It is a form of understand the regulator sends to firms when it deems a brand new drug or vaccine’s utility to be incomplete.
As a result of firms growing new merchandise meet with the FDA early within the procedure to agree on necessities for approval, it’s uncommon for the company to take this motion. What’s extra, there were only a few events through which the FDA has diverged considerably from different primary drug regulators all over the world. However on this case, drug regulators in Canada, Europe and Australia approved Moderna’s utility for evaluation.
Particularly regarding is that a number of FDA scientists and different team of workers have showed that they anticipated to study Moderna’s utility. The director of the FDA’s Place of work of Vaccines Analysis and Evaluation, David Kaslow, wrote a memo recommending it’s reviewed. However Vinay Prasad, who directs the middle that oversees the vaccine analysis place of business, overruled the verdict.
Administrators infrequently overrule company scientists, particularly referring to vaccines. However that is no less than the fourth time Prasad has performed so since being appointed to the FDA in 2025.
What causes did the FDA give for its choice?
Moderna took the ordinary step of saying the FDA’s refusal and freeing the company’s letter. The letter states that Moderna didn’t behavior an “adequate and well-controlled” learn about as it had no longer when compared sufferers receiving its vaccine to sufferers receiving what the company claimed to be “the best-available standard of care.”
Moderna’s flu vaccine will be the first one the use of mRNA generation, however Robert F. Kennedy Jr. and different federal well being officers had been skeptical concerning the protection of mRNA founded vaccines.
PixelVista/E+ by way of Getty Photographs
Within the U.S., standard-dose flu vaccines are licensed for everybody over 6 months of age, however well being government suggest that adults over 65 obtain a stronger dose. Moderna’s announcement quoted the language the FDA used when approving the corporate’s medical trial protocol in 2024. The company had at first urged that for folks age 65 and older, the corporate evaluate the efficacy of its vaccine to the stronger dose. However after reviewing Moderna’s protocol, the FDA deemed the usual vaccine “acceptable.”
But even so the truth that the FDA agreed to the rigors Moderna carried out, I consider the company’s declare that the corporate didn’t use “the best-available standard of care” is problematic as it does no longer replicate the felony necessities for vaccine approval. Even supposing this word sounds reputable, it’s nowhere to be present in FDA regulation or steerage for firms growing vaccines.
As a substitute, FDA regulation calls for an organization to supply knowledge from “adequate and well controlled studies” and the use of normal dose flu vaccines aligns with the requirement as a result of they’re broadly used throughout age teams.
From a felony standpoint, the FDA’s choice may probably meet what’s referred to as the “arbitrary and capricious” normal, since the company turns out to have altered its place with no legitimate explanation why for that fluctuate. If a courtroom makes the sort of decision, it would invalidate the FDA’s choice. That procedure, then again, would take time.
Does the FDA’s choice replicate a metamorphosis in vaccine coverage?
That is the primary time that the FDA has attempted to preclude the evaluation of a vaccine for causes that would not have to do with protection or efficacy. The transfer, which ties right into a broader technique by means of federal well being officers beneath Kennedy, alerts an escalation within the company’s efforts to intrude in established procedures for checking out vaccines.
In April 2025, Kennedy introduced that new vaccines will require further medical trials. In November 2025, Prasad launched an inner FDA memo claiming that mRNA-based COVID-19 vaccines had killed youngsters. Even supposing he equipped no proof, he mentioned that in accordance with the alleged deaths, large-scale adjustments to necessities for vaccine approval had been coming.
The FDA’s refusal of Moderna’s utility seems to be Prasad’s coverage in motion.
What would possibly this imply for vaccines going ahead?
On a realistic stage, the truth that the FDA is now articulating necessities which can be nowhere to be discovered within the regulation creates primary uncertainty for firms with pending or upcoming vaccine programs. That’s as a result of producers now have explanation why to fret that they may make investments assets within the long technique of growing a vaccine, simplest to obtain in a similar way unpredictable refusals.
Extra widely, with such a lot of spaces in vaccine regulation and coverage in turmoil, incentives for vaccine producers to convey vaccines to marketplace are shrinking. In January 2026, even sooner than the flu vaccine refusal, Moderna’s leader govt officer mentioned the corporate used to be scaling again on vaccine construction .
In any case, the FDA’s transfer dangers fueling additional distrust in vaccines, aligning with a much wider push from federal well being officers to query long-settled science.
